Crossmark

Transforming Perspectives in Cardiac Cell Therapy: Hypothesis and Commentary Following Updated Results of a Pilot Study Investigating Very Long-Term Clinical Outcomes in Severe AMI Patients Following Trans-Epicardial Injection of Peripheral Blood CD34+ Cells

Crossref DOI link: https://doi.org/10.1007/s12015-023-10643-w

Published Online: 2023-10-20

Published Print: 2024-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hénon, Philippe http://orcid.org/0000-0002-8798-5994
Bischoff, Nicolas

Dallemand, Robert
Funding

Funding for this research was provided by:

French Ministry of Health
License Information

Text and Data Mining valid from 2023-10-20

Version of Record valid from 2023-10-20
More Information

Article History

Accepted: 12 October 2023

First Online: 20 October 2023

Declarations

:

: All patients gave their written informed consent. The study was launched after the approval of the “Comité de Protection des Personnes (CPP) Est-4 – Strasbourg”, and the authorization of the French Health Regulatory Agency (ANSM).The study was conducted according to the Guidelines of the Declaration of Helsinki.

: The pilot study was supported by a grant of the French Ministry of Health.

: P.H. is staff member and stakeholder of CellProthera.

Document is current

Any future updates will be listed below